PEG-COATED POLY(LACTIC ACID) NANOPARTICLES FOR THE DELIVERY OF HEXADECAFLUORO ZINC PHTHALOCYANINE TO EMT-6 MOUSE MAMMARY-TUMORS

被引:84
作者
ALLEMANN, E
BRASSEUR, N
BENREZZAK, O
ROUSSEAU, J
KUDREVICH, SV
BOYLE, RW
LEROUX, JC
GURNY, R
VANLIER, JE
机构
[1] UNIV SHERBROOKE,FAC MED,MRC,RADIAT SCI GRP,SHERBROOKE,PQ J1H 5N4,CANADA
[2] UNIV GENEVA,SCH PHARM,GENEVA,SWITZERLAND
关键词
D O I
10.1111/j.2042-7158.1995.tb05815.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hexadecafluoro zinc phthalocyanine (ZnPcF(16)), a second generation sensitizer for the photodynamic therapy of cancer, was incorporated in three vehicles: poly(D,L-lactic acid) (PLA) nanoparticles, polyethylene glycol (PEG)-coated nanoparticles and a Cremophor EL (CRM) oil-water emulsion. Nanoparticles were prepared by the salting-out procedure. Biodistribution of the dye was assessed by fluorescence in EMT-6 mammary tumour bearing mice after intravenous injection of 1 mu mol kg(-1) ZnPcF(16). Plain nanoparticles were rapidly retained by the reticuloendothelial system (RES) as reflected by the low area under the blood concentration-time curve (AUC(0-168), 57 mu g h g(-1)). Little tumour uptake of the dye was observed with this formulation. In contrast, PEG-coated nanoparticles displayed a reduced RES uptake, leading to significantly higher blood levels over an extended period (t1/2 30 h; AUC(0-168) 227 mu g h g(-1)) and enhanced tumour uptake. At 48 h post injection, tumour to skin and tumour to muscle concentration ratios reached 3.5 and 10.8, respectively. Blood levels of ZnPcF(16) after administration as a CRM emulsion decreased faster than with PEG-coated nanoparticles (t1/2 12 h), but since no early liver uptake was observed, the AUC(0-168) and the tumour uptake were only slightly lower. However, with the CRM formulation, a late liver uptake was observed, reaching 51% of the injected dose after 7 days.
引用
收藏
页码:382 / 387
页数:6
相关论文
共 34 条
[1]   IN-VITRO EXTENDED-RELEASE PROPERTIES OF DRUG-LOADED POLY(DL-LACTIC ACID) NANOPARTICLES PRODUCED BY A SALTING-OUT PROCEDURE [J].
ALLEMANN, E ;
LEROUX, JC ;
GURNY, R ;
DOELKER, E .
PHARMACEUTICAL RESEARCH, 1993, 10 (12) :1732-1737
[2]  
ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P173
[3]  
ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P13
[4]   PREPARATION OF AQUEOUS POLYMERIC NANODISPERSIONS BY A REVERSIBLE SALTING-OUT PROCESS - INFLUENCE OF PROCESS PARAMETERS ON PARTICLE-SIZE [J].
ALLEMANN, E ;
GURNY, R ;
DOELKER, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 87 (1-3) :247-253
[5]   UNUSUAL SERUM LIPOPROTEIN ABNORMALITY INDUCED BY VEHICLE OF MICONAZOLE [J].
BAGNARELLO, AG ;
LEWIS, LA ;
MCHENRY, MC ;
WEINSTEIN, AJ ;
NAITO, HK ;
MCCULLOUGH, AJ ;
LEDERMAN, RJ ;
GAVAN, TL .
NEW ENGLAND JOURNAL OF MEDICINE, 1977, 296 (09) :497-499
[6]  
BIRCHALL JM, 1970, J CHEM SOC C, V9, P2667
[7]  
BOYLE RW, 1991, EUR SOC PHOTOBIOL C, P58
[8]   ADSORPTION OF HEMATOPORPHYRIN ONTO POLYALKYLCYANOACRYLATE NANOPARTICLES - CARRIER CAPACITY AND DRUG RELEASE [J].
BRASSEUR, N ;
BRAULT, D ;
COUVREUR, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1991, 70 (1-2) :129-135
[9]  
BRASSEUR N, 1993, J MED CHEM, V37, P415
[10]   DETERMINATION OF POLYETHYLENE-GLYCOL IN GAMMA-GLOBULIN SOLUTIONS [J].
CHILDS, CE .
MICROCHEMICAL JOURNAL, 1975, 20 (02) :190-192